Bionano Genomics agreed to acquire BioDiscovery, a software company specializing in genomics data, for $100m. This grants them access to BioDiscovery’s Nx Clinical software, which the company plans to integrate into their optical genome mapping software. The NX uses next-generation sequencing and microarray data to provide data analysis and visualization of copy number variants and single-nucleotide variants, providing a consolidated view of the genome. "This acquisition accelerates our efforts to make OGM ubiquitous by enabling us to simplify the assessment of clinically-relevant variants in cytogenomics applications, potentially reducing interpretation time per sample and expanding our reach into the discovery and translational research markets where the combination of NGS and OGM can reveal more answers in genetic disease and cancer research," Erik Holmlin, Bionano Genomics CEO.